PDGFRB and neoplasm: As both, regorafenib and infigratinib target pro-angiogenic growth factor receptors (VEGFRs/PDGFR and FGFRs), we hypothesised that this heterogeneity could be due to variations in the production of growth factor substrates by the tumour cells.